Literature DB >> 25840530

Management of 1- to 2-cm Carcinoid Tumors of the Appendix: Using the National Cancer Data Base to Address Controversies in General Surgery.

Daniel P Nussbaum1, Paul J Speicher2, Brian C Gulack2, Jeffrey E Keenan2, Asvin M Ganapathi2, Brian R Englum2, Douglas S Tyler2, Dan G Blazer2.   

Abstract

BACKGROUND: The management of 1- to 2-cm appendiceal carcinoid tumors remains controversial. Here we use the National Cancer Data Base (NCDB) to compare long-term outcomes for patients treated via resection of the primary tumor alone vs right hemicolectomy (RHC). STUDY
DESIGN: The 1998 to 2011 NCDB User File was queried to identify patients with 1- to 2-cm appendiceal carcinoids. Patients were stratified by surgical technique: resection of the primary tumor alone vs RHC with regional lymphadenectomy. Multivariable logistic regression was used to compare short-term outcomes. Survival was estimated using the Kaplan-Meier method with comparisons based on the log-rank test.
RESULTS: A total of 916 patients were identified, including 42% managed with primary resection and 58% with RHC. Patients who underwent RHC had slightly larger tumors and higher-stage tumors; otherwise, there were no baseline differences between groups. The rates of positive margins were similar (5.5% vs 4.5%; p = 0.60). Among all patients, 1- and 5-year survival were 98.1% and 88.7% vs 96.7% and 87.4% (p = 0.52) for those managed via primary resection vs RHC, respectively. Among patients with moderate/high-grade/anaplastic carcinoids, 1- and 5-year survival were 93.3% and 72.0% vs 92.3% and 71.9%, respectively (p = 0.78). After adjustment with Cox proportional hazards modeling, we confirmed that there was no survival benefit for patients undergoing RHC (hazard ratio = 1.14; p = 0.72).
CONCLUSIONS: For 1- to 2-cm appendiceal carcinoids, formal resection of the right colon does not appear to improve survival, even for higher-grade tumors. Our findings suggest that resection of the primary tumor alone is adequate for all carcinoids <2 cm.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25840530     DOI: 10.1016/j.jamcollsurg.2015.01.005

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  10 in total

1.  Practice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors.

Authors:  Danielle R Heller; Raymond A Jean; Jiajun Luo; Vadim Kurbatov; Gabriella Grisotti; Daniel Jacobs; Alexander S Chiu; Yawei Zhang; Sajid A Khan
Journal:  J Am Coll Surg       Date:  2019-03-19       Impact factor: 6.113

2.  Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity.

Authors:  Shayna Brathwaite; Jonathan Rock; Martha M Yearsley; Tanios Bekaii-Saab; Lai Wei; Wendy L Frankel; John Hays; Christina Wu; Sherif Abdel-Misih
Journal:  Ann Surg Oncol       Date:  2016-03-10       Impact factor: 5.344

Review 3.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Authors:  Francesca Fermi; Valentina Andreasi; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Curr Oncol Rep       Date:  2022-01-25       Impact factor: 5.075

4.  Pathologic Factors Associated with Low Risk of Lymph Node Metastasis in Nonmucinous Adenocarcinoma of the Appendix.

Authors:  Richard J Straker; Samuel Z Grinberg; Cimarron E Sharon; Adrienne B Shannon; Douglas L Fraker; Skandan Shanmugan; John T Miura; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2022-01-05       Impact factor: 5.344

Review 5.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

Review 6.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24

7.  Gastrointestinal mixed adenoneuroendocrine carcinoma: a population level analysis of epidemiological trends.

Authors:  Jiakun Wang; Aoxiao He; Qian Feng; Ping Hou; Junjun Wu; Zhihao Huang; Zhouqing Xiao; Chi Sun; Wenjun Liao; Linquan Wu
Journal:  J Transl Med       Date:  2020-03-14       Impact factor: 5.531

8.  Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Yibo Cai; Zhuo Liu; Lai Jiang; Dening Ma; Zhenyuan Zhou; Haixing Ju; Yuping Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-21       Impact factor: 6.055

9.  Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry.

Authors:  Shayna Brathwaite; Martha M Yearsley; Tanios Bekaii-Saab; Lai Wei; Carl R Schmidt; Mary E Dillhoff; Wendy L Frankel; John L Hays; Christina Wu; Sherif Abdel-Misih
Journal:  Front Oncol       Date:  2016-06-13       Impact factor: 6.244

10.  Operative Versus Nonoperative Management of Appendicitis: A Long-Term Cost Effectiveness Analysis.

Authors:  Lindsay A Sceats; Seul Ku; Alanna Coughran; Britainy Barnes; Emily Grimm; Matthew Muffly; David A Spain; Cindy Kin; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  MDM Policy Pract       Date:  2019-08-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.